Summary of FDA new draft guidance on safety reporting obligations for investigators
Most of the information about the safety of a drug prior to marketing comes from clinical trials. Adverse event reports from investigators are therefore critically important, given that it is the investigators who observe subjects responses to an investigational drug. The investigator must immediately report to the sponsor any SAEs, …